Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Katrin Aslan"'
Autor:
Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We i
Externí odkaz:
https://doaj.org/article/6a562891133f4ee084b42c34b2d77b3e
Autor:
Katrin Aslan, Verena Turco, Jens Blobner, Jana K. Sonner, Anna Rita Liuzzi, Nicolás Gonzalo Núñez, Donatella De Feo, Philipp Kickingereder, Manuel Fischer, Ed Green, Ahmed Sadik, Mirco Friedrich, Khwab Sanghvi, Michael Kilian, Frederik Cichon, Lara Wolf, Kristine Jähne, Anna von Landenberg, Lukas Bunse, Felix Sahm, Daniel Schrimpf, Jochen Meyer, Allen Alexander, Gianluca Brugnara, Ralph Röth, Kira Pfleiderer, Beate Niesler, Andreas von Deimling, Christiane Opitz, Michael O. Breckwoldt, Sabine Heiland, Martin Bendszus, Wolfgang Wick, Burkhard Becher, Michael Platten
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Modeling patient-individual resistance to immunotherapy is challenging. Here, the authors use a syngeneic experimental hypermutated orthotopic glioma model to define radiological and biological features that can predict or explain the mechanistic dif
Externí odkaz:
https://doaj.org/article/65441a7f16a24904a9e706ac1ace56b2
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Autor:
Luigi Buonaguro, Hans-Georg Rammensee, Harpreet Singh-Jasuja, Roberto S. Accolla, Toni Weinschenk, Carsten Reinhardt, Ulrike Gnad-Vogt, Mercedes Iñarrairaegui, Roberta Penta, Caterina Fusco, Maria Tagliamonte, Greta Forlani, Cécile Gouttefangeas, Regina Heidenreich, Tanguy Chaumette, Danila Valmori, Marco Borrelli, Heiko Schuster, Regina Mendrzyk, Katrin Aslan, Christian Flohr, Diego Duarte Alcoba, Jörg Ludwig, Antonio Avallone, Alessandro Inno, Luisa Vonghia, Sven Francque, Bruno Sangro, Yuk Ting Ma, Alfred Königsrainer, Paolo A. Ascierto, Andrea Mayer-Mokler, Francesco Izzo, Stefania Gori, Markus W. Löffler
Purpose:Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial for HCC (NCT03203005). It combines mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72da2ecb08d0ce79371835731a463971
https://doi.org/10.1158/1078-0432.c.6532524.v1
https://doi.org/10.1158/1078-0432.c.6532524.v1
Autor:
Luigi Buonaguro, Hans-Georg Rammensee, Harpreet Singh-Jasuja, Roberto S. Accolla, Toni Weinschenk, Carsten Reinhardt, Ulrike Gnad-Vogt, Mercedes Iñarrairaegui, Roberta Penta, Caterina Fusco, Maria Tagliamonte, Greta Forlani, Cécile Gouttefangeas, Regina Heidenreich, Tanguy Chaumette, Danila Valmori, Marco Borrelli, Heiko Schuster, Regina Mendrzyk, Katrin Aslan, Christian Flohr, Diego Duarte Alcoba, Jörg Ludwig, Antonio Avallone, Alessandro Inno, Luisa Vonghia, Sven Francque, Bruno Sangro, Yuk Ting Ma, Alfred Königsrainer, Paolo A. Ascierto, Andrea Mayer-Mokler, Francesco Izzo, Stefania Gori, Markus W. Löffler
Supplementary Data from Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974db9314e1841dc5d5fb343fce288cc
https://doi.org/10.1158/1078-0432.22487466.v1
https://doi.org/10.1158/1078-0432.22487466.v1
Autor:
Philipp C. Münch, Lukas Bunse, Camila Fernández-Zapata, Josef Priller, Oliver Schnell, Sabine Heiland, Jürgen Beck, Edward W. Green, Chotima Böttcher, Denis Abu-Sammour, Francisco J. Quintana, Roman Sankowski, Felix Sahm, Carina Ramallo Guevara, Wolfgang Wick, Khwab Sanghvi, Tobias Kessler, Tim Trobisch, Frederik Cichon, Carsten Hopf, Lucas Schirmer, Michael Platten, Dieter Henrik Heiland, Miriam Ratliff, Anna von Landenberg, Theresa Bunse, Jana K. Sonner, Daniel Schrimpf, Mirco Friedrich, Marco Prinz, Hagen M. Gegner, Ilona Gutcher, Stefan Pusch, Michael Kilian, Gernot Poschet, Katrin Aslan, Markus Hahn, Andreas von Deimling
Publikováno v:
Nature cancer 2(7), 723-740 (2021). doi:10.1038/s43018-021-00201-z
The dynamics and phenotypes of intratumoral myeloid cells during tumor progression are poorly understood. Here we define myeloid cellular states in gliomas by longitudinal single-cell profiling and demonstrate their strict control by the tumor genoty
Autor:
Kevin Hai-Ning Lu, Julius Michel, Michael Kilian, Katrin Aslan, Hao Qi, Niklas Kehl, Stefanie Jung, Khwab Sanghvi, Katharina Lindner, Xin-Wen Zhang, Edward W Green, Isabel Poschke, Miriam Ratliff, Theresa Bunse, Felix Sahm, Andreas von Deimling, Wolfgang Wick, Michael Platten, Lukas Bunse
Background Glioblastoma (GBM) is characterized by low numbers of glioma-infiltrating lymphocytes (GIL) with a dysfunctional phenotype. Whether this dysfunctional phenotype is fixed or can be reversed upon ex vivo culturing is poorly understood. The a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8da8ccc6cbb7af0fed6a5e10990e578
https://www.ncbi.nlm.nih.gov/pubmed/36196364
https://www.ncbi.nlm.nih.gov/pubmed/36196364
Autor:
Markus W. Löffler, Stefania Gori, Francesco Izzo, Andrea Mayer-Mokler, Paolo A. Ascierto, Alfred Königsrainer, Yuk Ting Ma, Bruno Sangro, Sven Francque, Luisa Vonghia, Alessandro Inno, Antonio Avallone, Jörg Ludwig, Diego Duarte Alcoba, Christian Flohr, Katrin Aslan, Regina Mendrzyk, Heiko Schuster, Marco Borrelli, Danila Valmori, Tanguy Chaumette, Regina Heidenreich, Cécile Gouttefangeas, Greta Forlani, Maria Tagliamonte, Caterina Fusco, Roberta Penta, Mercedes Iñarrairaegui, Ulrike Gnad-Vogt, Carsten Reinhardt, Toni Weinschenk, Roberto S. Accolla, Harpreet Singh-Jasuja, Hans-Georg Rammensee, Luigi Buonaguro
Publikováno v:
Clinical cancer research
Purpose: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial for HCC (NCT03203005). It combines mu
Autor:
Verena Turco, Chin Leng Tan, Dennis Alexander Agardy, Katrin Aslan, Katharina Lindner, Edward W. Green, Michael Platten, Theresa Bunse
Publikováno v:
WFNOS 2022 Abstract Book.
Autor:
Martin Bendszus, Jochen Meyer, Andreas von Deimling, Katrin Aslan, Michael O. Breckwoldt, Edward W. Green, Felix Sahm, Chin Leng Tan, Jens Blobner, Lukas Bunse, Manuel Fischer, Michael Kilian, Michael Platten, Khwab Sanghvi, Wolfgang Wick, Kristine Jähne
Publikováno v:
Neuro-oncology Advances
Background Glioblastomas, the most common primary malignant brain tumors, are considered immunologically cold malignancies due to growth in an immune sanctuary site. While peptide vaccines have shown to generate intra-tumoral antigen-specific T cells